CETP and SGLT2 inhibitor combination therapy improves glycemic control

IMPORTANCE: Cholesteryl ester transfer protein (CETP) inhibition has been associated with decreased risk of new-onset diabetes in past clinical trials exploring their efficacy in cardiovascular disease and can potentially be repurposed to treat metabolic disease. Notably, as an oral drug it can pote...

Descripción completa

Detalles Bibliográficos
Autores principales: Khomtchouk, Bohdan B., Sun, Patrick, Ditmarsch, Marc, Kastelein, John J.P., Davidson, Michael H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10312876/
https://www.ncbi.nlm.nih.gov/pubmed/37398493
http://dx.doi.org/10.1101/2023.06.13.23291357

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10312876/
https://www.ncbi.nlm.nih.gov/pubmed/37398493
http://dx.doi.org/10.1101/2023.06.13.23291357

Ejemplares similares